The UK Divide: Does having a Pembrolizumab-Chemotherapy option in head and neck cancer matter? Real-world experience of first-line palliative pembrolizumab monotherapy and pembrolizumab-chemotherapy combination in Scotland DOI Creative Commons
Alekh Thapa, Anna Cowell, Adam Peters

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2023, Volume and Issue: unknown

Published: June 12, 2023

Abstract Objectives The Scottish Medical Consortium recently approved first-line pembrolizumab monotherapy or in combination with chemotherapy for head and neck squamous cell carcinoma (HNSCC) the palliative setting, contrasting decision made by National Institute Health Care Excellence who alone England Wales. We aimed to provide real-world performance data pembrolizumab-containing treatments setting Scotland. Materials Methods analysed electronic records of patients initiated treatment between 01/03/2020–30/09/2021. Outcomes included overall survival (OS), progression-free (PFS), duration response (DOR), disease control rate (DCR). Data were compared KEYNOTE-048 study clinical factors evaluated association survival. Results Our cohort 91 (median follow-up 10.8 months). Patient characteristics similar though our had a higher proportion newly diagnosed, non-metastatic disease. For receiving (n=76), 12-month 24-month OS was 45% 27%, respectively. pembrolizumab-chemotherapy (n=15), 60% (24-month not yet been reached). Experiencing ≥1 irAE (versus no irAEs), any grade, associated favourable PFS both univariable log-rank analysis 17.4 months versus 8.6 months, respectively, P=0.0033; median 10.9 3.0 P<0.0001) multivariable (Cox proportional hazards regression: HR: 0.31, P=0.0009; 0.17, P<0.0001). Conclusion support findings value options. Additionally, show irAEs as reported routine records, are better outcomes this patient group, adding growing body evidence showing generally positive marker PD-L1 inhibitor response.

Language: Английский

Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma DOI Creative Commons
Adam Barsouk,

John Sukumar Aluru,

Prashanth Rawla

et al.

Medical Sciences, Journal Year: 2023, Volume and Issue: 11(2), P. 42 - 42

Published: June 13, 2023

Head and neck squamous cell carcinoma (HNSCC) is a group of malignancies, involving the oral cavity, pharynx, hypopharynx, larynx, nasal salivary glands, that together compose seventh most common cancer diagnosis worldwide. With 890,000 new cases 450,000 deaths annually per GLOBOCAN estimates, HNSCC accounts for roughly 4.5% diagnoses deaths. In developing world, incidence growing with increasing consumption tobacco (smoked or chewed), alcohol, areca nut (betel quid). Alcohol have synergistic effect, heavy both risk 40-fold. developed nations, HPV-related surpasses tobacco- alcohol-related disease. more commonly affects oropharynx, larynx than associated significantly longer median survival (130 months vs. 20 months). Discrepancies in etiology as well disparities lifestyle choices access to healthcare may account greater poorer among minority lower-socioeconomic-status communities nations. Pharmacotherapy counseling been shown be effective promoting smoking alcohol cessation. Education on community engagement reduced Asia diaspora communities. HPV vaccination, starting at age 11–12 sexes, has reduce prevalence high-risk serologies prevent pre-cancerous lesions cervix, vagina, vulva. As 2020, 58.6% eligible adolescents US received full two-vaccine series. Increased adoption education safe sex practices, routine visual screening patients would curb

Language: Английский

Citations

316
The UK Divide: Does Having a Pembrolizumab–Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab–Chemotherapy Combination in Scotland DOI
Alekh Thapa, Anna Cowell, Adam Peters

et al.

Clinical Oncology, Journal Year: 2024, Volume and Issue: 36(5), P. 287 - 299

Published: Feb. 12, 2024

Language: Английский

Citations

4
Advanced Stage Head and Neck Cancer Diagnosis: HEADSpAcE Consortium Health Systems Benchmarking Survey DOI Creative Commons
Grant Creaney, Mariél de Aquino Goulart, Alex D. McMahon

et al.

Head & Neck, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 24, 2025

ABSTRACT Background Globally, most people with head and neck cancers (HNCs) are diagnosed advanced‐stage disease. HNC diagnostic stage has multifactorial explanations, the role of health system factors not yet fully investigated. Methods centres ( n = 18) from HEADSpAcE Consortium were surveyed via a bespoke questionnaire covering range factors. Centres compared using least square means for presence/absence each factor to their proportion HNC. Results Health associated lower in diagnosis formal referral triaging (14%, 95% CI‐0.26, −0.03), routine monitoring time (16%, CI‐0.27, −0.05), publicly funded systems (17%, CI‐0.29, −0.06). Several had no routinely available data. Conclusions Through identifying proportions advanced HNC, interventions could be developed, redesigned, improve early diagnosis.

Language: Английский

Citations

0
Genetic, clinical, lifestyle and sociodemographic risk factors for head and neck cancer: A UK Biobank study DOI Creative Commons
Lisa Tuomi, Toshima Z. Parris, Araz Rawshani

et al.

PLoS ONE, Journal Year: 2025, Volume and Issue: 20(4), P. e0318889 - e0318889

Published: April 4, 2025

Introduction Despite a steady decline in tobacco smoking, head and neck cancer (HNC) incidence rates are on the rise. Therefore, novel risk factors for HNC needed to identify at-risk patients at an early stage. Here, we used genetic, clinical, lifestyle, sociodemographic data from UK Biobank (UKB) evaluate relative importance of known predictors risk. Methods All participants UKB between 2006 2021 were stratified into cases controls baseline (cases: n = 534; controls: 501833) or during follow-up 1587; 500246). A cross-sectional description (clinical characteristics, lifestyle sociodemographic) was performed, followed by multivariate Cox regression analysis (adjusted age sex) gradient boosting machine learning determine (phenotypic SNPs) development after baseline. Results In addition (age, male sex, smoking alcohol consumption habits, occupation), show that cessation ≤ 40 years is strongest predictor Although SNPs may play role development, predictive model containing phenotypic variables (C-index 0.75) did not significantly outperform alone 0.73). Conclusion Taken together, this study demonstrates such as past occupation, facial pain, education, pulmonary function, anthropometric measures can be predict

Language: Английский

Citations

0
Interventions for the treatment of oral cavity and oropharyngeal cancers: surgical treatment DOI
Helen V Worthington, Vishal M Bulsara, Anne‐Marie Glenny

et al.

Cochrane library, Journal Year: 2023, Volume and Issue: 2023(8)

Published: Aug. 31, 2023

Language: Английский

Citations

9
Advancements in Hyperspectral Imaging and Computer-Aided Diagnostic Methods for the Enhanced Detection and Diagnosis of Head and Neck Cancer DOI Creative Commons
I‐Chen Wu, Yen‐Chun Chen, Riya Karmakar

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(10), P. 2315 - 2315

Published: Oct. 11, 2024

Background/Objectives: Head and neck cancer (HNC), predominantly squamous cell carcinoma (SCC), presents a significant global health burden. Conventional diagnostic approaches often face challenges in terms of achieving early detection accurate diagnosis. This review examines recent advancements hyperspectral imaging (HSI), integrated with computer-aided (CAD) techniques, to enhance HNC Methods: A systematic seven rigorously selected studies was performed. We focused on CAD algorithms, such as convolutional neural networks (CNNs), support vector machines (SVMs), linear discriminant analysis (LDA). These are applicable the tissues. Results: The meta-analysis findings indicate that LDA surpasses other an accuracy 92%, sensitivity 91%, specificity 93%. CNNs exhibit moderate performance, 82%, 77%, 86%. SVMs demonstrate lowest 76% 48%, but maintain high level at 89%. Additionally, vivo superior performance when compared ex studies, reporting higher (81%), (83%), (79%). Conclusion: Despite these promising findings, persist, HSI’s external conditions, need for high-resolution high-speed imaging, lack comprehensive spectral databases. Future research should emphasize dimensionality reduction integration multiple machine learning models, development extensive libraries clinical utility diagnostics. underscores transformative potential HSI techniques revolutionizing diagnostics, facilitating more earlier detection, improving patient outcomes.

Language: Английский

Citations

3
Head and neck cancer incidence is rising but the sociodemographic profile is unchanging: a population epidemiological study (2001–2020) DOI Creative Commons
Craig D. Smith, Alex D. McMahon, Mitana Purkayastha

et al.

BJC Reports, Journal Year: 2024, Volume and Issue: 2(1)

Published: Sept. 17, 2024

Language: Английский

Citations

2
The stage of head and neck diagnosed malignancies in COVID‐19 outbreak versus before outbreak: A retrospective study DOI Creative Commons
Fatemeh Jahanshahi, Mahboobe Asadi, Alireza Movahedi

et al.

Cancer Reports, Journal Year: 2023, Volume and Issue: 6(5)

Published: March 16, 2023

Abstract Background Global COVID‐19 pandemic has affected cancer care systems. Recent studies show that the number of cases diagnosed with drastically decreased compared to same period before pandemic. Therefore, we are confronted delayed diagnosis critical cancers. Aim The aim this study is investigate whether stage known cancers been by and compare stages head neck during Methods present was conducted on 132 patients malignant tumors referred otolaryngology, department Taleghani Hospital from 2019 2021. between two groups malignancy Otolaryngology, Head Neck Department outbreak. Results results tumor (T), nodes (N), metastases (M) (TNM) staging ( p ‐value = .015) T score (value 0.045) showed in significantly increased a Conclusion In study, it observed early symptoms have neglected resulted diagnosis. This result may be explained fear infection patients, which discouraged them visiting doctor at healthcare centers.

Language: Английский

Citations

4
Clinical photodynamic therapy: The evolution of photodynamic therapy treatment of head and neck cancer DOI

Merrill A. Biel

Journal of Porphyrins and Phthalocyanines, Journal Year: 2024, Volume and Issue: 28(06), P. 338 - 348

Published: March 17, 2024

The modern era of photodynamic therapy (PDT) treatment human cancer began in earnest 1978, with the publication by Dougherty et al. first large series humans refractory or recurrent skin cancers successfully treated PDT using HpD (Photofrin). head and neck patients (Photofrin) was published 1985, Keller Since that time, numerous clinical investigators around world have thousands trials. These trials enrolled various stages disease, locations tumor were a variety photosensitizers. Head treatments performed as primary intent to cure, late-stage for palliation tumor, an adjuvant neoadjuvant combination surgery, radiation, chemotherapy most recently immunotherapy. Over past five decades, has evolved newer more targeted photosensitizers became available use, well advances laser fiberoptic technologies allowing activating light be easily delivered deep into invasive tumors. In addition, can accurately endoscopic, robotic, CT, ultrasound MRI guidance thereby specifically targeting reducing morbidity. Significant progress been achieved ease use efficacy disease.

Language: Английский

Citations

1
Development and external validation of a head and neck cancer risk prediction model DOI Creative Commons
Craig D. Smith, Alex D. McMahon, Donald M. Lyall

et al.

Head & Neck, Journal Year: 2024, Volume and Issue: 46(9), P. 2261 - 2273

Published: June 8, 2024

Abstract Background Head and neck cancer (HNC) incidence is on the rise, often diagnosed at late stage associated with poor prognoses. Risk prediction tools have a potential role in prevention early detection. Methods The IARC‐ARCAGE European case–control study was used as model development dataset. A clinical HNC risk using behavioral demographic predictors developed via multivariable logistic regression analyses. then externally validated UK Biobank cohort. Model performance tested discrimination calibration metrics. Results 1926 cases 2043 controls were for of model. dataset including sociodemographic, smoking, alcohol variables had moderate discrimination, an area under curve (AUC) value 0.75 (95% CI, 0.74–0.77); slope (0.75) tests suggestive good calibration. 384 616 participants (with 1177 cases) available external validation Upon validation, AUC 0.62 0.61–0.64). Conclusion We ARCAGE studies, respectively. This population acceptable Demographics behaviors are strong HNC, this may be helpful tool primary dental care settings to promote determine recall intervals examination. Future addition HPV serology or genetic factors could further enhance individual prediction.

Language: Английский

Citations

1